Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





IVD Market Exceeded USD 50 Billion in 2011

By LabMedica International staff writers
Posted on 18 Jul 2012
AACC 2012: A market research company reports that the world market for in vitro diagnostics (IVD) is estimated at USD 50.9 billion for 2011.

According to a report by the healthcare market research publisher, Kalorama Information (New York, NY, USA) growth in the IVD market is driven by an aging population, product innovations, and sales to emerging markets. More...
Kalorama revealed its findings as the industry meets and assesses its progress at the annual 2012 meeting of the American Association for Clinical Chemistry (AACC), which is being held in Los Angeles (CA, USA) from July 15-July 19, 2012.

The revenue estimate for 2011 includes all laboratory and hospital-based products, and over-the-counter (OTC) product sales. The report found that the IVD market has grown but it will be challenged with a sharp decline in pricing for diagnostic tests in Europe and consolidation in the US, which could lead to price erosion.

“A number of world events bode well for the future of medical devices: an aging worldwide population and demand for new hospitals in developing countries,” said Shara Rosen, Kalorama diagnostic analyst and author of the report. “Increasing numbers of people between the ages of 45 and 75 years in the industrialized world consume more healthcare services such as heart and cancer tests.”

Some of the total market growth expected in the coming years could derive from increased test usage in emerging countries. Significant growth is expected in Brazil, China, and India, which are investing in healthcare infrastructure and insurance coverage for a growing, more affluent middle class.

The new availability of choices, undoubtedly good for medical care, poses problems for the physician who must choose correctly from among the numerous new IVD products, and for payers to pay for new technologies that may still be unproven.

Some of the total market growth expected in the coming years could derive from increased test usage in emerging countries. Significant growth is expected in Brazil, China, and India, which are investing in healthcare infrastructure and insurance coverage for a growing, more affluent middle class.

“IVD companies are casting their nets in developing countries, where rising incomes and standards of living have sparked a new health consciousness and growing demands for quality medical care,” remarked Shara Rosen.

Related Links:

Kalorama Information



Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Collection and Transport System
PurSafe Plus®
New
Gold Member
Collection and Transport System
PurSafe Plus®
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.